Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 4 · 100%High 0 · 0%

a) Cerebral palsy or gross motor disability · preterm infants at risk for apnea

Methylxanthine showed no clear difference in a) Cerebral palsy or gross motor disability compared with placebo or control (moderate certainty).

1 finding from 1 review

Methylxanthine for the prevention and treatment of apnea in preterm infants 2023 · Cochrane Headline outcomes only
RR 1.03 [0.43, 2.49]
1 study · 415 participants
Moderate

a) Cerebral palsy or gross motor disability · preterm infants with apnea

Methylxanthine showed no clear difference in a) Cerebral palsy or gross motor disability compared with placebo or control (moderate certainty).

1 finding from 1 review

Methylxanthine for the prevention and treatment of apnea in preterm infants 2023 · Cochrane Headline outcomes only
RR 0.6 [0.29, 1.25]
1 study · 729 participants
Moderate

a) Cerebral palsy or gross motor disability · preterm infants prior to extubation

Methylxanthine probably leads to lower a) Cerebral palsy or gross motor disability compared with placebo or control (moderate certainty).

1 finding from 1 review

Methylxanthine for the prevention and treatment of apnea in preterm infants 2023 · Cochrane Headline outcomes only
RR 0.54 [0.32, 0.92]
1 study · 644 participants
Moderate

a) Cerebral palsy or gross motor disability · preterm infants at risk of or with apnea; preterm infants undergoing extubation

Methylxanthine probably leads to lower a) Cerebral palsy or gross motor disability compared with placebo or control (moderate certainty).

1 finding from 1 review

Methylxanthine for the prevention and treatment of apnea in preterm infants 2023 · Cochrane Headline outcomes only
RR 0.6 [0.41, 0.88]
1 study · 1810 participants
Moderate